176 related articles for article (PubMed ID: 29100312)
1. Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases.
Østrup O; Dagenborg VJ; Rødland EA; Skarpeteig V; Silwal-Pandit L; Grzyb K; Berstad AE; Fretland ÅA; Mælandsmo GM; Børresen-Dale AL; Ree AH; Edwin B; Nygaard V; Flatmark K
Oncotarget; 2017 Sep; 8(44):76290-76304. PubMed ID: 29100312
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemotherapy is associated with a transient increase of intratumoral T-cell density in microsatellite stable colorectal liver metastases.
Dagenborg VJ; Marshall SE; Yaqub S; Grzyb K; Boye K; Lund-Iversen M; Høye E; Berstad AE; Fretland ÅA; Edwin B; Ree AH; Flatmark K
Cancer Biol Ther; 2020 May; 21(5):432-440. PubMed ID: 32098573
[TBL] [Abstract][Full Text] [Related]
3. De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity.
Moosavi SH; Eide PW; Eilertsen IA; Brunsell TH; Berg KCG; Røsok BI; Brudvik KW; Bjørnbeth BA; Guren MG; Nesbakken A; Lothe RA; Sveen A
Genome Med; 2021 Sep; 13(1):143. PubMed ID: 34470666
[TBL] [Abstract][Full Text] [Related]
4. Intrahepatic CD69
Bruni E; Cimino MM; Donadon M; Carriero R; Terzoli S; Piazza R; Ravens S; Prinz I; Cazzetta V; Marzano P; Kunderfranco P; Peano C; Soldani C; Franceschini B; Colombo FS; Garlanda C; Mantovani A; Torzilli G; Mikulak J; Mavilio D
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35863820
[TBL] [Abstract][Full Text] [Related]
5. Consensus molecular subtype classification of colorectal adenomas.
Komor MA; Bosch LJ; Bounova G; Bolijn AS; Delis-van Diemen PM; Rausch C; Hoogstrate Y; Stubbs AP; de Jong M; Jenster G; van Grieken NC; Carvalho B; Wessels LF; Jimenez CR; Fijneman RJ; Meijer GA;
J Pathol; 2018 Nov; 246(3):266-276. PubMed ID: 29968252
[TBL] [Abstract][Full Text] [Related]
6. Seed and Soil: Consensus Molecular Subgroups (CMS) and Tumor Microenvironment Features Between Primary Lesions and Metastases of Different Organ Sites in Colorectal Cancer.
Luo Q; Quan Y; Liu W; Wu Z; Qiu W; Liang W; Yang P; Huang Q; Li G; Wei J; Wang Q; Shen F; Li W; He F; Cao J
Cancer Manag Res; 2024; 16():225-243. PubMed ID: 38525373
[TBL] [Abstract][Full Text] [Related]
7. Metastatic heterogeneity of the consensus molecular subtypes of colorectal cancer.
Eide PW; Moosavi SH; Eilertsen IA; Brunsell TH; Langerud J; Berg KCG; Røsok BI; Bjørnbeth BA; Nesbakken A; Lothe RA; Sveen A
NPJ Genom Med; 2021 Jul; 6(1):59. PubMed ID: 34262039
[TBL] [Abstract][Full Text] [Related]
8. Optimal indication criteria for neoadjuvant chemotherapy in patients with resectable colorectal liver metastases.
Ichida H; Mise Y; Ito H; Ishizawa T; Inoue Y; Takahashi Y; Shinozaki E; Yamaguchi K; Saiura A
World J Surg Oncol; 2019 Jun; 17(1):100. PubMed ID: 31196104
[TBL] [Abstract][Full Text] [Related]
9. Multidisciplinary approach of colorectal liver metastases.
Juez I; Rubio C; Figueras J
Clin Transl Oncol; 2011 Oct; 13(10):721-7. PubMed ID: 21975333
[TBL] [Abstract][Full Text] [Related]
10. T cell receptor repertoire sequencing reveals chemotherapy-driven clonal expansion in colorectal liver metastases.
Høye E; Dagenborg VJ; Torgunrud A; Lund-Andersen C; Fretland ÅA; Lorenz S; Edwin B; Hovig E; Fromm B; Inderberg EM; Greiff V; Ree AH; Flatmark K
Gigascience; 2022 Dec; 12():. PubMed ID: 37161965
[TBL] [Abstract][Full Text] [Related]
11. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
[TBL] [Abstract][Full Text] [Related]
12. Low Concordance Between T-Cell Densities in Matched Primary Tumors and Liver Metastases in Microsatellite Stable Colorectal Cancer.
Dagenborg VJ; Marshall SE; Grzyb K; Fretland ÅA; Lund-Iversen M; Mælandsmo GM; Ree AH; Edwin B; Yaqub S; Flatmark K
Front Oncol; 2021; 11():671629. PubMed ID: 34178659
[TBL] [Abstract][Full Text] [Related]
13. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.
Mooi JK; Wirapati P; Asher R; Lee CK; Savas P; Price TJ; Townsend A; Hardingham J; Buchanan D; Williams D; Tejpar S; Mariadason JM; Tebbutt NC
Ann Oncol; 2018 Nov; 29(11):2240-2246. PubMed ID: 30247524
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases.
Andreou A; Kopetz S; Maru DM; Chen SS; Zimmitti G; Brouquet A; Shindoh J; Curley SA; Garrett C; Overman MJ; Aloia TA; Vauthey JN
Ann Surg; 2012 Oct; 256(4):642-50. PubMed ID: 22968062
[TBL] [Abstract][Full Text] [Related]
15. Treatment strategies for colorectal carcinoma with synchronous liver metastases: Which way to go?
Ihnát P; Vávra P; Zonča P
World J Gastroenterol; 2015 Jun; 21(22):7014-21. PubMed ID: 26078580
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiles of CMS2-epithelial/canonical colorectal cancers are largely driven by DNA copy number gains.
Berg KCG; Sveen A; Høland M; Alagaratnam S; Berg M; Danielsen SA; Nesbakken A; Søreide K; Lothe RA
Oncogene; 2019 Aug; 38(33):6109-6122. PubMed ID: 31308487
[TBL] [Abstract][Full Text] [Related]
17. Genomic and prognostic heterogeneity among RAS/BRAF
Berg KCG; Brunsell TH; Sveen A; Alagaratnam S; Bjørnslett M; Hektoen M; Brudvik KW; Røsok BI; Bjørnbeth BA; Nesbakken A; Lothe RA
Mol Oncol; 2021 Apr; 15(4):830-845. PubMed ID: 33325154
[TBL] [Abstract][Full Text] [Related]
18. Classification of patients with metastatic colorectal cancer into consensus molecular subtypes into real-world: A pilot study.
González-Montero J; Burotto M; Valenzuela G; Mateluna D; Buen-Abad F; Toro J; Barajas O; Marcelain K
World J Clin Oncol; 2023 Oct; 14(10):409-419. PubMed ID: 37970108
[TBL] [Abstract][Full Text] [Related]
19. Consensus Molecular Subtypes of Colorectal Cancer and their Clinical Implications.
Thanki K; Nicholls ME; Gajjar A; Senagore AJ; Qiu S; Szabo C; Hellmich MR; Chao C
Int Biol Biomed J; 2017; 3(3):105-111. PubMed ID: 28825047
[TBL] [Abstract][Full Text] [Related]
20. The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications.
Soldevilla B; Carretero-Puche C; Gomez-Lopez G; Al-Shahrour F; Riesco MC; Gil-Calderon B; Alvarez-Vallina L; Espinosa-Olarte P; Gomez-Esteves G; Rubio-Cuesta B; Sarmentero J; La Salvia A; Garcia-Carbonero R
Eur J Cancer; 2019 Dec; 123():118-129. PubMed ID: 31678770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
